Table 2.

Outcomes After CAR-T Administration

Outcome	All Patients (N = 78)
Cytokine release syndrome	66 (85%)
None	12 (15%)
Grade 1	28 (36%)
Grade 2	28 (36%)
Grade 3	8 (10%)
Grade 4	2 (3%)
Neurotoxicity	52 (67%)
None	26 (33%)
Grade 1	17 (22%)
Grade 2	13 (17%)
Grade 3	22 (28%)
Tocilizumab	48 (62%)
Dexamethasone	38 (49%)
Response to therapy
Remission/positive response	43 (55%)
Progression	28 (36%)
Unable to gauge response	3 (4%)
Death during admission for CAR-T	4 (5%)

Abbreviation: CAR-T, chimeric antigen receptor therapy.